Evidence map›Paper›PMID 28648303›Full record

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2017

Risk of ESRD and Mortality Associated With Change in Filtration Markers.

Casey M Rebholz, Lesley A Inker, Yuan Chen, Menglu Liang, Meredith C Foster, John H Eckfeldt, Paul L Kimmel, Ramachandran S Vasan, Harold I Feldman, Mark J Sarnak and 4 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Casey M RebholzDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: crebhol1@jhu.edu.
Lesley A InkerWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Yuan ChenDepartment of Biostatistics, Columbia University Mailman School of Public Health, New York, NY.
Menglu LiangDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Meredith C FosterWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
John H EckfeldtDepartment of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Ramachandran S VasanSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA; Section of Cardiology, Department of Medicine, Boston University School of Medicine, Boston, MA.
Harold I FeldmanDepartment of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Mark J SarnakWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Chi-Yuan HsuDivision of Nephrology, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA.
Andrew S LeveyWilliam B. Schwartz Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
Josef CoreshDepartment of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Chronic Kidney Disease Biomarkers Consortium
Tufts Medical Center · USJohns Hopkins University · USBoston University · USColumbia University · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of California, San Francisco · USUniversity of Minnesota · USUniversity of Pennsylvania · US

Funding

Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Metabolomics for Identifying Biomarkers of Dietary Intake & Kidney Disease ProgressionK01DK107782 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI REBHOLZ, CASEY MARIE · 2016 to 2020
$778k
NIDDK NIH HHS K01 DK107782NIDDK NIH HHS U01 DK085689
6 · The paper itself

Abstract

backgroundUsing change in estimated glomerular filtration rate (eGFR) based on creatinine concentration as a surrogate outcome in clinical trials of chronic kidney disease has been proposed. Risk for end-stage renal disease (ESRD) and all-cause mortality associated with change in concentrations of other filtration markers has not been studied in chronic kidney disease populations. STUDY

designObservational analysis of 2 clinical trials. SETTING &

participantsParticipants in the MDRD (Modification of Diet in Renal Disease; n=317) Study and AASK (African American Study of Kidney Disease and Hypertension; n=373). PREDICTORS: Creatinine, cystatin C, β-trace protein (BTP), and β OUTCOMES: ESRD and all-cause mortality. MEASUREMENTS: Poisson regression was used to estimate incidence rate ratios and 95% CIs for ESRD and all-cause mortality during long-term follow-up (10-16 years) per 30% decline in mGFR or eGFR for each filtration marker and the average of all 4 markers.

results1-year decline in mGFR, eGFR LIMITATIONS: Small sample size.

conclusionsDeclines in mGFR, eGFR

Indexed as

Glomerular Filtration RateBiomarkersClinical Trials as TopicFemaleHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRisk AssessmentBiomarkersBeta-2-microglobulin (B2M)beta trace protein (BTP)creatininecystatin Cdeathend-stage renal disease (ESRD)estimated GFRfiltration markersglomerular filtration rate (GFR)incident ESRDkidney function declinemeasured GFRmortality

Identifiers

PMID28648303
PMCPMC5610931
OpenAlexW2676598516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.